QURE uniQure NV

  1. Stocks
  2. Healthcare
  3. NASDAQ: QURE

Price (delayed)

$47.06

Market cap

$3.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.01

Enterprise value

$3.4B

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 24

uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with ...

Highlights
The equity has soared by 117% QoQ
The gross profit has grown by 46% YoY and by 5% from the previous quarter
The net income has declined by 27% year-on-year and by 21% since the previous quarter
The company's EPS fell by 15% QoQ and by 2.3% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.uniqure.com
Peers: AMGN BMRN

Key stats

What are the main financial stats of QURE

QURE stock price

How has the uniQure stock price performed over time
Intraday
4.28%
1 week
3.75%
1 month
14.5%
1 year
222.33%
YTD
96.66%
QTD
2.17%

Financial performance

How have uniQure's revenue and profit performed over time
Revenue
$18.67M
Gross profit
$17.27M
Operating income
-$200.08M
Net income
-$252.21M
Gross margin
92.5%
Net margin
-1,350.7%
The gross profit has grown by 46% YoY and by 5% from the previous quarter
The company's revenue rose by 30% YoY and by 3.2% QoQ
The net income has declined by 27% year-on-year and by 21% since the previous quarter
QURE's operating income is down by 18% YoY and by 4.3% QoQ

Price vs fundamentals

How does QURE's price correlate with its fundamentals

Growth

What is uniQure's growth rate over time

Valuation

What is uniQure stock price valuation
P/E
N/A
P/B
9.16
P/S
166.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
182.28
The company's EPS fell by 15% QoQ and by 2.3% YoY
The equity has soared by 117% QoQ
QURE's P/B is 104% above its 5-year quarterly average of 4.5
The company's revenue rose by 30% YoY and by 3.2% QoQ
The P/S is 28% higher than the last 4 quarters average of 130.6

Efficiency

How efficient is uniQure business performance
The return on equity has surged by 89% year-on-year and by 23% since the previous quarter
The company's return on sales fell by 26% QoQ and by 5% YoY
The return on invested capital has declined by 22% since the previous quarter and by 9% year-on-year
The ROA has grown by 13% YoY but it has contracted by 7% from the previous quarter

Dividends

What is QURE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QURE.

Financial health

How did uniQure financials performed over time
QURE's total assets is 49% greater than its total liabilities
QURE's total assets has surged by 68% year-on-year and by 27% since the previous quarter
The total liabilities has grown by 12% YoY and by 5% from the previous quarter
The debt is 70% higher than the equity
The equity has soared by 117% QoQ
The debt to equity has soared by 101% YoY but it has plunged by 53% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.